Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After $1Bn manufacturing issues, Weldon to make way as J&J picks insider Gorsky for CEO

This article was originally published in Scrip

Executive Summary

Johnson & Johnson has announced that its CEO of the past 10 years, Bill Weldon, is to stand down in April, making way for Alex Gorsky, current head of the group's medical devices and diagnostics division. It is not clear if Mr Weldon's departure was forced by the string of manufacturing quality issues and product recalls that have knocked $1 billion off J&J's sales, but succession planning had been going on for some time. Mr Weldon will stay on in his existing role as chairman of the board of directors.Mr Gorsky was one of two internal candidates being groomed as potential successors to Mr Weldon. He and Sheri McCoy, who runs the pharmaceuticals and consumer product groups of the US healthcare giant, were both named vice-chairs of the executive committee back in January 2011 as part of the process, which also looked at outside candidates. Mr Weldon described the decision as the conclusion of a "rigorous, thorough and formal multi-year process".

You may also be interested in...

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus

Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts